Ocugen, Inc. (NASDAQ: OCGN) will host an in-person Clinical Showcase on November 12, 2024, in New York City, highlighting advancements in its retinal gene therapy programs. The event will feature updates from ongoing clinical trials, including those for retinitis pigmentosa (RP), geographic atrophy (GA), and Stargardt disease.
The showcase will provide a clinical update on the Phase 3 liMeliGhT trial for retinitis pigmentosa, along with new data from Phase 1/2 trials for RP and Leber congenital amaurosis (LCA). Preliminary safety and efficacy data from the Phase 1/2 OCU410 ArMaDa clinical trial for geographic atrophy will also be presented.
Updates on Stargardt Disease and Diabetic Macular Edema
Ocugen will also share a clinical trial progress report from the Phase 1/2 OCU410ST GARDian study for Stargardt disease. In addition, the company will provide background information on its biologic candidate, OCU200, for diabetic macular edema, with plans to initiate a Phase I clinical trial this quarter.
Expert Insights and Patient Perspectives
The event will feature presentations from Ocugen's leadership team, including Dr. Shankar Musunuri, Chairman, CEO & Co-founder; Dr. Huma Qamar, Chief Medical Officer; and Dr. Arun Upadhyay, Chief Scientific Officer & Head of R&D. Study investigators, such as Dr. Benjamin Bakall, Dr. Lejla Vajzovic, and Dr. Syed M. Shah, will also participate. The program will conclude with a patient panel representing participants in Ocugen’s ongoing clinical trials, offering valuable perspectives on their experiences.
